



# HHS Public Access

Author manuscript

*Ann Intern Med.* Author manuscript; available in PMC 2016 January 24.

Published in final edited form as:

*Ann Intern Med.* 2015 July 21; 163(2): 81–90. doi:10.7326/M15-0530.

## Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States

**Requests for Single Reprints:** Allison M. Liddell, MD, Texas Health Presbyterian Hospital Dallas, 8230 Walnut Hill Lane, Suite 308, Dallas, TX 75231; allisonliddell@texashealth.org.

Current author addresses and author contributions are available at [www.annals.org](http://www.annals.org).

**Current Author Addresses:** Drs. Liddell, Brown, and Tseggay: Texas Health Presbyterian Hospital Dallas, 8230 Walnut Hill Lane, Suite 308, Dallas, TX 75231.

Dr. Davey: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, CRC 4-1479, 10 Center Drive, MSC 1460, Bethesda, MD 20892-1504.

Dr. Mehta: Division of Infectious Diseases, Emory University School of Medicine, 101 Woodruff Circle, WMRB 2101, Atlanta, GA 30322.

Dr. Varkey: Emory University School of Medicine, 1364 Clifton Road NE, B-701, Atlanta, GA 30322.

Dr. Kraft: Emory University School of Medicine, 1364 Clifton Road NE, F145C, Atlanta, GA 30322.

Dr. Badidi: Texas Health Presbyterian Hospital Dallas, 8200 Walnut Hill Lane, Dallas, TX 75231.

Dr. Faust: Department of Pharmacy, Texas Health Presbyterian Hospital Dallas, 8200 Walnut Hill Lane, Dallas, TX 75231.

Dr. Suffredini: Critical Care Medicine Department, National Institutes of Health Clinical Center, 10/2C, 10 Center Drive, Bethesda, MD 20892.

Mr. Barrett: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Drive, Room 5-5563, Bethesda, MD 20892.

Dr. Wolcott: U.S. Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702.

Dr. Marconi: Emory University School of Medicine, 341 Ponce de Leon Avenue, Room 345, Atlanta, GA 30308.

Dr. Lyon: Emory University School of Medicine, 101 Woodruff Circle, WMB 2101, Atlanta, GA 30322.

Drs. Weinstein, Weinmeister, Sutton, and Hazbun: Texas Health Presbyterian Hospital Dallas, 8220 Walnut Hill Lane, Suite 408, Dallas, TX 75231.

Dr. Albariño, Ströher, and Uyeki; Mr. Reed; and Ms. Cannon: Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329.

Dr. Feldman: Department of Internal Medicine, Texas Health Presbyterian Hospital Dallas, 8200 Walnut Hill Lane, Dallas, TX 75231.

Dr. Ribner: Emory University Hospital, 1364 Clifton Road NE, Suite B705, Atlanta, GA 30322.

Dr. Lane: National Institutes of Health, Building 10, Room 11S 231, MSC 1894, Bethesda, MD 20892.

Dr. Fauci: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 31, Room 7A-03, 31 Center Drive, MSC 2520, Bethesda, MD 20892-2520.

**Disclaimer:** The opinions expressed in this article are the authors' own and do not represent any position or policy of the Centers for Disease Control and Prevention, the National Institutes of Health, the U.S. Department of Health and Human Services, the U.S. Army, or the U.S. government.

**Disclosures:** Dr. Weinstein reports personal fees from Glaxo-SmithKline, Pfizer, and Boston Scientific outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at [www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-0530](http://www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-0530).

**Reproducible Research Statement:** *Study protocol, statistical code, and data set:* Not applicable.

**Author Contributions:** Conception and design: A.M. Liddell, R.T. Davey, A.K. Mehta, G.M. Lyon, M. Feldman, B.S. Ribner, T.M. Uyeki.

Analysis and interpretation of the data: A.M. Liddell, R.T. Davey, A.K. Mehta, J.B. Varkey, G.K. Tseggay, K.V. Brown, M.J.

Wolcott, V.C. Marconi, K. Weinmeister, U. Ströher, M. Feldman, B.S. Ribner, H.C. Lane, A.S. Fauci, T.M. Uyeki.

Drafting of the article: A.M. Liddell, R.T. Davey, A.K. Mehta, G.K. Tseggay, A.C. Faust, A.F. Suffredini, M.J. Wolcott, M. Hazbun, M. Feldman, B.S. Ribner.

Critical revision of the article for important intellectual content: A.M. Liddell, R.T. Davey, A.K. Mehta, C.S. Kraft, O. Badidi, K.V.

Brown, A.F. Suffredini, K. Barrett, V.C. Marconi, G.M. Lyon, G.L. Weinstein, U. Ströher, M. Feldman, B.S. Ribner, T.M. Uyeki.

Final approval of the article: R.T. Davey, A.K. Mehta, J.B. Varkey, C.S. Kraft, G.K. Tseggay, O. Badidi, A.C. Faust, K.V. Brown,

A.F. Suffredini, K. Barrett, V.C. Marconi, G.M. Lyon, M. Hazbun, U. Ströher, M. Feldman, B.S. Ribner, H.C. Lane, A.S. Fauci, T.M. Uyeki.

Provision of study materials or patients: A.M. Liddell, R.T. Davey, A.K. Mehta, C.S. Kraft, G.K. Tseggay, O. Badidi, K.V. Brown,

A.F. Suffredini, K. Barrett, V.C. Marconi, G.M. Lyon, G.L. Weinstein, B.S. Ribner. Statistical expertise: M. Feldman.

Administrative, technical, or logistic support: R.T. Davey, J.B. Varkey, K. Barrett, M.J. Wolcott, Z. Reed, D. Cannon, U. Ströher, M. Feldman, T.M. Uyeki.

Collection and assembly of data: A.M. Liddell, R.T. Davey, A.K. Mehta, A.C. Faust, K.V. Brown, K. Barrett, M.J. Wolcott, M. Hazbun, C.G. Albariño, Z. Reed, M. Feldman.

Allison M. Liddell, MD, Richard T. Davey Jr., MD, Aneesh K. Mehta, MD, Jay B. Varkey, MD, Colleen S. Kraft, MD, MSc, Gebre K. Tseggay, MD, Oghenetega Badidi, MD, Andrew C. Faust, PharmD, Katia V. Brown, MD, Anthony F. Suffredini, MD, Kevin Barrett, RN, Mark J. Wolcott, PhD, Vincent C. Marconi, MD, G. Marshall Lyon III, MD, MMSc, Gary L. Weinstein, MD, Kenney Weinmeister, MD, Shelby Sutton, MD, Munir Hazbun, MD, César G. Albariño, PhD, Zachary Reed, MPH, Debi Cannon, Ute Ströher, PhD, Mark Feldman, MD, Bruce S. Ribner, MD, MPH, H. Clifford Lane, MD, Anthony S. Fauci, MD, and Timothy M. Uyeki, MD, MPH, MPP

Texas Health Presbyterian Hospital Dallas, Dallas, Texas; National Institutes of Health Clinical Center, Bethesda, Maryland; Emory University School of Medicine and Centers for Disease Control and Prevention, Atlanta, Georgia; and U.S. Army Medical Research Institute of Infectious Diseases, Frederick, Maryland

## Abstract

**Background**—More than 26 000 cases of Ebola virus disease (EVD) have been reported in western Africa, with high mortality. Several patients have been medically evacuated to hospitals in the United States and Europe. Detailed clinical data are limited on the clinical course and management of patients with EVD outside western Africa.

**Objective**—To describe the clinical characteristics and management of a cluster of patients with EVD, including the first cases of Ebola virus (EBOV) infection acquired in the United States.

**Design**—Retrospective clinical case series.

**Setting**—Three U.S. hospitals in September and October 2014.

**Patients**—First imported EVD case identified in the United States and 2 secondary EVD cases acquired in the United States in critical care nurses who cared for the index case patient.

**Measurements**—Clinical recovery, EBOV RNA level, resolution of Ebola viremia, survival with discharge from hospital, or death.

**Results**—The index patient had high EBOV RNA levels, developed respiratory and renal failure requiring critical care support, and died. Both patients with secondary EBOV infection had nonspecific signs and symptoms and developed moderate illness; EBOV RNA levels were moderate, and both patients recovered.

**Limitation**—Both surviving patients received uncontrolled treatment with multiple investigational agents, including convalescent plasma, which limits generalizability of the results.

**Conclusion**—Early diagnosis, prompt initiation of supportive medical care, and moderate clinical illness likely contributed to successful outcomes in both survivors. The inability to determine the potential benefit of investigational therapies and the effect of patient-specific factors that may have contributed to less severe illness highlight the need for controlled clinical studies of these interventions, especially in the setting of a high level of supportive medical care.

**Primary Funding Source**—None.

---

Ebola virus (EBOV) infections have caused extraordinary morbidity and mortality among persons in Guinea, Sierra Leone, and Liberia since late 2013 (1–6). More than 850 cases of

Ebola virus disease (EVD) have been reported among health care personnel in western Africa (5). On 30 September 2014, the first case of EVD identified in the United States was confirmed in a Liberian man who traveled from Liberia to Dallas, Texas, on 20 September and became ill 4 days later. He was admitted to an intensive care unit (ICU) isolation room on 29 September and died on 8 October. Subsequently, 2 nurses who had cared for this patient in the ICU became ill and were diagnosed with EVD. In this article, we review the clinical and laboratory data for these 3 patients and describe the clinical course and management of the index patient and the first 2 patients with EBOV infection acquired in the United States.

## Methods

Clinical and laboratory testing data for the patients were collected retrospectively at the 3 hospitals where they received care, and the data were reviewed and described. Results of molecular testing for EBOV RNA and serologic data were also collected and described.

### Laboratory Methods for Molecular Detection of EBOV

**Texas Department of State Health Services Virology Laboratory**—The QIAGEN QIAamp Viral RNA Mini Kit was used according to the manufacturer's instructions to purify RNA from whole blood specimens, and reverse transcriptase polymerase chain reaction (RT-PCR) was performed according to the instruction booklet for the Ebola Zaire (EZ1) rRT-PCR (TaqMan) Assay under emergency use authorization (7).

**Centers for Disease Control and Prevention**—The MagMAX Pathogen RNA/DNA Kit (Life Technologies) was used to purify RNA from specimens, and a quantitative RT-PCR (qRT-PCR) assay specific to the EBOV nucleoprotein gene was performed as previously described (8). A cycle threshold (Ct) value greater than 40 was considered negative. Enzyme-linked immunosorbent assays for IgM and IgG were performed as previously described (9).

**U.S. Army Medical Research Institute of Infectious Diseases**—The QIAGEN QIAamp Viral RNA Mini Kit was used to purify RNA from specimens, and RT-PCR was performed according to the instruction booklet for the Ebola Zaire (EZ1) rRT-PCR (TaqMan) Assay under emergency use authorization and as previously described (7, 10). A Ct value greater than or equal to 40 was considered negative.

### Role of the Funding Source

No specific funding was provided for this study. The authors' institutions had no role in the design or conduct of the study or the reporting of the data.

## Results

### Patient 1

The index case patient was a 42-year-old Liberian man who traveled from Monrovia, Liberia, and arrived in Dallas, Texas, on 20 September 2014. On 24 September (illness day

1), he developed abdominal pain, a cold feeling, and frontal headache, and he presented to the emergency department (ED) late on illness day 2 with abdominal pain, headache, rhinorrhea, and nasal congestion (Figure 1). He did not disclose recent travel from Liberia. His initial temperature was 37.8 °C (maximum, 39.4 °C), his heart rate was 90 beats/min, and his blood pressure was 119/72 mm Hg. His physical examination was remarkable only for mild, diffuse abdominal tenderness. Pertinent laboratory abnormalities included a total leukocyte count of  $3.08 \times 10^9$  cells/L, absolute lymphocyte count of  $0.77 \times 10^9$  cells/L, serum creatinine level of 124.6  $\mu\text{mol/L}$  (1.41 mg/dL), platelet count of  $92 \times 10^9$  cells/L, and serum aspartate amino-transferase (AST) level of 94 U/L (Figure 2 and Appendix Table 1, available at [www.annals.org](http://www.annals.org)). His serum glucose level was 10.0 mmol/L (180 mg/dL). Computed tomography scans of the head, abdomen, and pelvis without contrast were unremarkable. The patient was discharged home on illness day 3 with a prescription for azithromycin for presumed sinusitis.

The patient returned to the ED on illness day 5 with abdominal pain, diarrhea, fever, chills, headache, poor appetite, and generalized weakness. On arrival, he reported recent travel from Liberia but denied recent exposure to persons with known EVD or febrile illness in Liberia. He reported large-volume watery diarrhea occurring 6 to 8 times per day and 1 episode of nausea and vomiting 2 days earlier. His vital signs were a temperature of 39.5 °C, heart rate of 107 beats/min, blood pressure of 130/81 mm Hg, and respiratory rate of 22 breaths/min. His physical examination was remarkable for mild, diffuse abdominal tenderness that was worse in the right upper quadrant. Pertinent laboratory results included leukopenia, thrombocytopenia, hyponatremia, and elevated serum glucose and AST levels (Appendix Table 1). Results of a malaria rapid antigen test, a stool culture, and *Giardia* and *Cryptosporidium* antigen tests were negative, and results of chest radiography and abdominal ultrasonography were normal. While in the ED, the patient had projectile vomiting and explosive diarrhea. Because EVD was suspected, the patient was kept in an ED isolation room under standard, droplet, and contact precautions, and a blood specimen was collected for EBOV testing. Two liters of normal saline were administered by bolus infusion. Levofloxacin therapy was started empirically to treat enteric bacterial infections. The patient was transferred to an ICU isolation room on illness day 6, where he reported severe myalgia and arthralgia. Fluid resuscitation continued, with 2.4 L of normal saline plus a 1.5-L bicarbonate infusion started that day.

A team of infection preventionists trained ED staff during the initial hours of care and ICU staff before ICU transfer according to then-current guidelines from the Centers for Disease Control and Prevention. Additions to personal protective equipment (PPE) included full-body suits with head covering and powered airpurifying respirators beginning on the evening of illness day 7.

On illness day 7, abdominal pain and diarrhea (estimated at up to 10 L/d) persisted, and a rectal tube was placed for stool containment and measurement. Intravenous hydration continued, with 9.7 L of normal saline and 2.25 L of sodium bicarbonate solution in 5% dextrose in water given per 24 hours. Electrolyte replacement continued per routine ICU protocol. Levofloxacin was replaced with ertapenem. A peripherally inserted central catheter was placed for hydration and blood collection. Serum aminotransferase levels increased

sharply, with a peak serum AST level of 1308 U/L. Diarrhea remained copious, up to an estimated 8 L/d. Infection with EBOV was confirmed on illness day 7 by qRT-PCR (Ct value, 19) in the blood specimen collected on illness day 5. A blood specimen collected on illness day 6 yielded a Ct value of 17 by qRT-PCR for EBOV, reflecting high viral load. The patient's condition remained unchanged on illness day 8.

On illness day 9, the patient's fever continued. His antibiotics were changed to vancomycin, piperacillin–tazobactam, and levofloxacin because of concerns about possible health care–associated pneumonia and bacterial sepsis. The peak potassium supplementation was 120 mmol per 24 hours on illness day 9. Chest radiography revealed new bilateral pulmonary infiltrates consistent with pulmonary edema or pneumonia. Blood cultures were not performed because of risk to laboratory workers. A nephrology consultation diagnosed acute tubular necrosis. On illness day 10, piperacillin–tazobactam was replaced with meropenem because of worsening renal function on illness day 9 (creatinine level, 237.8  $\mu\text{mol/L}$  [2.69 mg/dL]) and decreasing platelet count. Fresh frozen plasma was administered for coagulopathy on illness days 9 and 10 (maximum international normalized ratio, 2.0 [Appendix Table 1]), with minimal bleeding from puncture sites. Intake and output were kept matched, electrolytes were replaced per standard ICU protocol, and 25% albumin infusions were administered every 6 hours on illness days 7 to 11. High levels of supplemental oxygen were required to maintain oxygen saturation (nonrebreather mask at 15 L of O<sub>2</sub> per minute) on illness day 9. Chest radiography showed bilateral diffuse pulmonary infiltrates. A dose of diphenoxylate–atropine was administered for diarrhea. The patient's blood type was B, and no suitable donor for convalescent plasma therapy was available.

Discussions were held with clinical partners who had experience in managing patients with EVD in the United States and with the U.S. Food and Drug Administration (FDA) regarding the availability and potential use of investigational therapeutics, and to weigh the potential benefits and harms of such treatments in a patient with elevated aminotransferase levels and severe diarrhea. ZMapp (an experimental cocktail of 3 EBOV-specific monoclonal antibodies [Mapp Biopharmaceutical]) was unavailable. On the basis of unpublished in vitro data, an emergency Investigational New Drug (eIND) application for brincidofovir (CMX-001 [Chimerix]) was made to the FDA.

On illness day 10, the patient developed oliguria, his serum creatinine level increased to 516.3  $\mu\text{mol/L}$  (5.84 mg/dL), and his fractional urinary excretion of sodium was 1.2%. Despite furosemide administration, anuria occurred. The patient was given a second dose of diphenoxylate–atropine. That night, he was sedated, medically paralyzed, and intubated for hypoxemic respiratory failure, and a hemodialysis catheter was placed. On illness day 11, his fever resolved, and continuous venovenous hemodialysis without anticoagulation was started using the NxStage system (Central Infusion Alliance). After informed consent by the patient's family and approval of an eIND request by the FDA and the hospital's institutional review board, the patient was given a 200-mg loading dose of brincidofovir via orogastric tube at 3:00 p.m. The continuous venovenous hemodialysis system clotted after 12 hours, and a citrate protocol was initiated. Stool output decreased to 1.4 L/d and then nearly stopped. Total parenteral nutrition was initiated and continued for 4 days. Later that day, the patient became hypotensive and required nor-epinephrine infusion.

On illness day 12, very high serum levels of AST and alanine aminotransferase (ALT) ( $>3600$  U/L) were attributed to propofol used for sedation (Figure 2 and Appendix Table 1). The patient's aminotransferase levels decreased but remained elevated after propofol was withdrawn. Micafungin was added empirically to the antimicrobial therapy. Stress doses of glucocorticoids were initiated, and the patient was weaned off norepinephrine.

The patient remained critically ill during illness days 12 to 14, with high oxygen requirements (Appendix Table 1). His total leukocyte count continued to increase (to  $51 \times 10^9$  cells/L), and he continued to receive vancomycin, meropenem, and micafungin. Diarrhea persisted throughout the patient's hospitalization and worsened with initiation of tube feedings. A blood specimen collected on illness day 13 had detectable IgM, but IgG antibodies to EBOV were not detected (Appendix Table 1). On illness day 14, the patient received a second dose of brincidofovir (100 mg). On illness day 15, his temperature increased to  $39.1$  °C, and profound hypotension developed rapidly. Treatment with vasopressors was restarted, and acidosis and hyperglycemia worsened, with his serum lactate level increasing to  $19.07$  mmol/L. Within 8 hours, bradycardia that did not respond to atropine developed, and pulseless electrical activity occurred. In accordance with the patient's earlier request for no chest compressions or cardioversion, no further resuscitation efforts were performed.

## Patient 2

Patient 2 was a previously healthy 26-year-old woman who provided critical care nursing for the index patient on 29 and 30 September and 1, 5, and 7 October 2014 (illness days 6 to 8, 12, and 14). She denied any known exposure event occurring while she was providing direct care to the index patient and wore more than the minimum PPE recommended as of September 2014, although this initially did not include complete head and neck coverage (11). On 9 October, she had a suspected exacerbation of allergic rhinitis with nasal congestion and rhinorrhea. She had an oral temperature of  $38.1$  °C on the night of 10 October (illness day 1) and presented to the ED at 1:00 a.m. on 11 October (Figure 1). She reported insomnia, slight headache, mild nasal congestion, and throat discomfort. She was placed in an ED isolation room designated for a person under investigation for EVD.

Her temperature was  $38.2$  °C, her heart rate was 117 beats/min, and her blood pressure was 138/100 mm Hg. Her physical examination was unremarkable. Laboratory results included a leukocyte count of  $4.1 \times 10^9$  cells/L, absolute lymphocyte count of  $0.66 \times 10^9$  cells/L, platelet count of  $343 \times 10^9$  cells/L, and AST level of 27 U/L (Appendix Table 2, available at [www.annals.org](http://www.annals.org)). A plasma specimen collected that day tested positive for EBOV RNA by RT-PCR (Ct value, 32). A nasopharyngeal swab was negative for a panel of respiratory pathogens by multiplex PCR.

The patient was admitted to an isolation room in the ICU. She remained stable, with intermittent fever, headache, nausea, and vomiting. She had no diarrhea during the first 4 days of her illness. A peripherally inserted central catheter was placed for intravenous hydration and blood specimen collection. The patient developed mild thrombocytopenia and anemia. Supportive care included close monitoring of fluids and electrolytes and treatment with acetaminophen, hydrocodone, ondansetron, phenazopyridine, meperidine, morphine,



diphenhydramine, pantoprazole, vitamins, electrolyte supplements, and protein-rich oral supplements. Antibiotics were not administered.

Multiple investigational therapies were administered with the patient's informed consent after approval of an eIND request by the FDA and the hospital's institutional review board (Table and Figures 1 and 3). She received oral brincidofovir in a 200-mg loading dose on illness day 3 and a 100-mg dose on illness day 6. Two 500-mL infusions of convalescent plasma (matched by blood type) from a recovered patient with onset of EVD 81 days earlier were administered on illness days 3 and 4 and were well-tolerated. On illness day 4, elevated serum aminotransferase levels were observed (Figure 3 and Appendix Table 2). The small interfering RNA molecule TKM-Ebola (Tekmira Pharmaceuticals) was administered intravenously at 0.3 mg/kg of body weight on illness day 4 after premedication with acetaminophen and diphenhydramine. Approximately 6 hours after the infusion started, the patient developed high fever (40.0 °C), rigors, and chills consistent with cytokine release syndrome from TKM-Ebola, and acetaminophen and meperidine were administered. She also developed tachycardia and systolic hypotension for several hours that responded to a 25% albumin infusion. On illness days 5 and 6, a reduced dosage of TKM-Ebola (0.24 mg/kg) was well-tolerated. On illness day 5, one 44.8-mg/kg (recommended dose, 50 mg/kg) intravenous dose of ZMapp was administered without adverse effects.

On illness day 5, before the ZMapp dose and the second TKM-Ebola dose, the patient developed a mild cough with dyspnea and was suspected to have pulmonary edema, with clinical improvement after a 20-mg intravenous dose of furosemide. A faint, diffuse morbilliform rash on the extremities and trunk was noted. On illness day 6, intermittent diarrhea occurred and an increase in serum aminotransferase levels was observed (Figure 3). On illness day 7, the patient was transferred to a hospital with a biocontainment patient care unit. At the time of transfer, she had been afebrile for 24 hours and had a semiformal stool. She reported increased energy and appetite and was ambulating.

On arrival at the second hospital, the patient had intermittent headaches and anorexia that persisted without fever for several days. She received 900 mL of normal saline per 24 hours (with potassium supplementation), followed by combined oral and intravenous hydration the next day and oral fluids thereafter. Given her clinical improvement, increasing Ct values (reflecting decreasing EBOV RNA levels), and unexplained increase in serum aminotransferase levels, further treatment with TKM-Ebola and brincidofovir was withheld (Figure 3). A blood specimen collected on illness day 8 was negative for EBOV by qRT-PCR. The patient's serum aminotransferase levels peaked on illness day 9 and then gradually decreased (Figure 3 and Appendix Table 2). Blood specimens collected for EBOV RNA testing on illness days 9 and 11 to 16 remained negative. Throat, rectal, vaginal, and urine specimens were negative for EBOV RNA on illness day 12, as were sweat samples collected from 2 different locations on illness day 14. Ebola virus-specific IgM and IgG antibodies were detected by enzyme-linked immunosorbent assay after receipt of convalescent plasma and ZMapp (Figure 3 and Appendix Table 2). The patient was discharged on illness day 15. In follow-up 12 days after discharge, her only reported symptom was arthralgia managed by nonsteroidal anti-inflammatory drugs; serum AST and ALT levels were 27 and 38 U/L, respectively (Appendix Table 2).

### Patient 3

Patient 3 was a previously healthy 29-year-old woman who provided critical care nursing for the index patient on 30 September and 1, 5, and 7 October 2014 (illness days 7, 8, 12, and 14). She denied any known exposure event occurring while she was providing direct care to the index patient and also wore more than the minimum PPE recommended as of September 2014 (11). Per instructions, she monitored her temperature and symptoms; other than fatigue and decreased appetite beginning on 10 October, she was asymptomatic. On 14 October, self-measured oral temperature readings were 37.9 °C and 38.1 °C, and she presented to the ED reporting that her eyes appeared jaundiced (Figure 1). The patient had 2 nonbloody diarrheal stools in the ED. Her physical examination was remarkable only for a faint erythematous macular rash on her left forearm that spread to her extremities and trunk, an oral temperature of 37.9 °C, tachycardia (138 beats/min), and anxiety. Initial abnormal laboratory results included a serum AST level of 255 U/L, ALT level of 175 U/L, platelet count of  $120 \times 10^9$  cells/L, leukocyte count of  $2.67 \times 10^9$  cells/L, and absolute lymphocyte count of  $0.62 \times 10^9$  cells/L (Appendix Table 3, available at [www.annals.org](http://www.annals.org)). She was placed in an ED isolation room designated for a person under investigation for EVD. Because of the high suspicion for EVD, empirical treatment with oral brincidofovir (200 mg) was started at 6:00 p.m. in the ED after approval of an eIND request by the FDA and the hospital's institutional review board (Table).

The patient's fever persisted, with a maximum oral temperature of 38.9 °C, but her tachycardia was alleviated with intravenous fluids. Her blood pressure remained normal and her oxygen saturation remained at 99% to 100% on room air, but she continued to have watery diarrhea. A blood specimen collected on 14 October was positive for EBOV RNA by qRT-PCR (Ct value, 30). The patient was transferred to the EVD isolation unit in the ICU and was then transferred to another hospital with a biocontainment patient care unit.

On arrival at the second hospital 1 day after fever onset, the patient had mild pruritus, nausea, anorexia, and diarrhea, but intravenous hydration was not needed. Approximately 38 hours after fever onset, 600 mL of blood type–matched convalescent plasma from a recovered patient with onset of EVD 85 days earlier was administered and was well-tolerated.

The patient's diarrhea continued the next day, but her serum aminotransferase levels decreased slightly and her leukopenia resolved (Appendix Table 3). An additional 500-mL dose of convalescent plasma from the same donor was administered and was well-tolerated. Three days after fever onset, her diarrhea resolved and her serum AST and ALT levels continued to decrease (Figure 4). Polymerase chain reaction testing of stool collected that day was positive for a *Campylobacter* species. On the evening of the fourth day after fever onset, shortly after receiving a second dose of oral brincidofovir (100 mg), the patient experienced transient swelling and erythema of both hands and a facial rash.

Five days after fever onset, the patient's serum AST and ALT levels began to increase again (Figure 4 and Appendix Table 3). During the next 3 days, she had multiple semiformal, steatorrheic-appearing bowel movements. Because her stool again tested positive for a *Campylobacter* species by PCR, the patient received oral azithromycin (500 mg) daily for 3



days. Loose stools continued for 2 more days, when she was placed on a low-fat diet, and her serum AST and ALT levels began to decrease. Thereafter, she experienced only mild fatigue and dyspnea with exertion and remained afebrile.

Testing of serial blood specimens by qRT-PCR indicated increasing Ct values over time, which reflected decreasing EBOV RNA levels. Ebola virus RNA was un-detectable 6 days after fever onset (Figure 4). Ebola virus-specific antibodies were first detected 3 days after fever onset and peaked 3 days later (Figure 4). However, as in patient 2, differentiation of intrinsic humoral responses from antibodies derived from the donor's plasma was not possible. Serial urine specimens were positive for EBOV RNA by qRT-PCR until 8 days after fever onset. Vaginal and skin swab specimens collected 9 and 12 days after fever onset, respectively, were both negative for EBOV RNA. The patient was discharged home 14 days after fever onset. Her serum AST and ALT levels 7 days after discharge were 42 and 137 U/L, respectively. On day 40 after fever onset, these levels were 24 U/L and 35 U/L, respectively (Appendix Table 3).

## Discussion

This cluster of EVD cases included the first domestically acquired EBOV infections in 2 critical care nurses who provided direct care to the first patient diagnosed with EVD in the United States. Despite aggressive supportive critical care, including invasive mechanical ventilation, vasopressors, and continuous renal replacement therapy, the index patient died. He received 2 doses of an investigational treatment (brincidofovir) on illness days 11 and 14, relatively late in his clinical course. Immunoglobulin M antibodies were detectable by illness day 6, although IgG was never detected. The index patient was older than the other patients and his Ct values reflected a high blood EBOV viral load—both poor prognostic indicators—and undiagnosed diabetes may also have contributed to his death. In addition, the history obtained from him may not have been accurate regarding onset of illness and exposure. The patient and his family denied EBOV exposure in discussions with multiple examiners and health department officials. Any reports of known exposure were obtained outside this hospital or the local health department. The secondary patients were young adults without co-morbid conditions, and neither had substantial gastrointestinal fluid losses or severe complications compared with other patients with EVD, including the index patient (2, 3, 12–14). Although the source and timing of transmission are unknown, the similarities of their clinical courses and virologic data suggest that both might have acquired EBOV infection during a similar period.

Patients 2 and 3 developed mild nonspecific symptoms and mildly elevated temperature before diagnosis of EVD. This suggests that the earliest signs and symptoms of EBOV infection may be mild, subtle, and nonspecific before fever onset, a finding that has implications for surveillance of persons with known exposure to a patient with EVD. Similarly, malaise and low-grade fever for 3 days before temperature elevation to greater than 38 °C were described in a Spanish patient with EVD (15). For patient 2, the possible incubation period between the last and earliest known exposures to the index patient and fever onset was 3 to 12 days.

Although the timing of illness onset in patient 3 is uncertain, the clinical (rash) and laboratory (leukopenia, lymphopenia, and thrombocytopenia) findings at fever onset and presentation were consistent with illness onset approximately 4 to 5 days earlier, based on the natural history of EVD (16). An alternative explanation for these findings is possible incipient *Campylobacter* enteric infection, although this was based on a positive stool PCR result without stool culture. Patient 3 had a possible incubation period of 3 to 15 days after exposure to the index patient and illness onset during 10 to 14 October 2014.

Both surviving patients received multiple investigational therapies, including convalescent plasma. Testing of blood specimens indicated moderately high Ct values by qRT-PCR, which reflected low to moderate EBOV RNA levels in both patients, with clearance of viremia correlating with resolution of clinical illness. However, the clinical benefit and relative effect of the investigational therapies on clearance of viremia are unknown because different treatments overlapped with each other and were uncontrolled. Use of these experimental therapies is supported only by uncontrolled observational findings in patients with EVD, in vitro data, and preclinical safety data from healthy volunteers or studies of use of these therapies in other viral illnesses. Given the moderate degree of illness in these patients and their low EBOV RNA levels, it is possible that both would have recovered with supportive care alone.

We were unable to attribute the observed elevations in serum aminotransferase levels after clinical improvement in both surviving patients to a specific agent or intervention. The observed patterns of ALT elevation that were similar to or higher than those for AST suggested potential drug toxicity rather than EBOV infection, which typically manifests as a marked elevation in serum AST levels compared with ALT levels (2, 12–14). Serum ALT elevation has been reported with brincidofovir treatment (17). In patient 2, this uncertainty about potential drug toxicity influenced the decision to withdraw 2 experimental agents.

This experience provides evidence that survival of patients with EVD can be improved by timely provision of full hemodynamic support, including aggressive fluid replacement, and diagnosis and correction of metabolic derangements (2, 3, 12–14, 16–19). It also highlights a need for controlled clinical trials of investigational therapies, including convalescent plasma. Such trials need to be conducted among patients with EVD in low-resource settings in western Africa and in facilities in developed countries.

## Acknowledgment

The authors thank the entire staff of Texas Health Presbyterian Hospital Dallas, particularly Edward Goodman, MD, Beverly Dickson, MD, Otto Javier Marquez-Kerguelen, MD, Sarah S. Way, MD, Mark Till, MD, Glen Owen, MD, Bruce Wall, MD, Elaine Whitaker, MD, David Gonzales, MD, and Sarita Sharma-Louys, MD; Texas Health Resources for its unwavering support; William Dorman and Samantha Tostenson of the U.S. Army Medical Research Institute of Infectious Diseases for technical work on RT-PCR assays; David Henderson, MD, and Tara Palmore, MD, of the National Institutes of Health Clinical Center for their infection control leadership; the nursing and hospital epidemiology staff at the National Institutes of Health Clinical Center for their outstanding patient care; Anne Winkler, MD, of the Emory University Hospital Serious Communicable Diseases Unit for coordinating the convalescent plasma collection and administration; all of the members of the Emory University Hospital Serious Communicable Diseases Unit team for their outstanding contributions to the patient's excellent care (supported by award UL1TR000454 from the National Center for Advancing Translational Sciences of the National Institutes of Health [Atlanta Clinical and Translational Science Institute]); and Tara Sealy, MS, Aridith Gibbons, and Bobbie Rae Erickson, MPH, of the Centers for Disease Control and Prevention for their technical support on the laboratory assays.

## References

1. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magas-souba N, et al. Emergence of Zaire Ebola virus disease in Guinea. *N Engl J Med*. 2014; 371:1418–1425. [PMID: 24738640]. [PubMed: 24738640]
2. Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, et al. KGH Lassa Fever Program. Clinical illness and outcomes in patients with Ebola in Sierra Leone. *N Engl J Med*. 2014; 371:2092–2100. [PMID: 25353969]. [PubMed: 25353969]
3. Bah EI, Lamah MC, Fletcher T, Jacob ST, Brett-Major DM, Sall AA, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. *N Engl J Med*. 2015; 372:40–47. [PMID: 25372658]. [PubMed: 25372658]
4. WHO Ebola Response Team. Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections. *N Engl J Med*. 2014; 371:1481–1495. [PMID: 25244186]. [PubMed: 25244186]
5. World Health Organization. Ebola Situation Report—6 May 2015. Geneva: World Health Organization; 2015. Accessed at [http://apps.who.int/iris/bitstream/10665/164523/1/roadmapsitrep\\_6May15\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/164523/1/roadmapsitrep_6May15_eng.pdf) on 6 May 2015.
6. Agua-Agum J, Ariyaratna A, Aylward B, Blake IM, Brennan R, Cori A, et al. WHO Ebola Response Team. West African Ebola epidemic after one year—slowing but not yet under control [Letter]. *N Engl J Med*. 2015; 372:584–587. [PMID: 25539446]. [PubMed: 25539446]
7. Naval Medical Research Center. Ebola Zaire (EZ1) rRT-PCR (Taq-Man®) Assay on ABI® 7500 Fast Dx, LightCycler®, and JBAIDS. Instruction Booklet. 2014. Accessed at [www.fda.gov/downloads/MedicalDevices/Safety/EmergencySituations/UCM418802.pdf](http://www.fda.gov/downloads/MedicalDevices/Safety/EmergencySituations/UCM418802.pdf) on 17 April 2015
8. Towner JS, Sealy TK, Ksiazek TG, Nichol ST. High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings. *J Infect Dis*. 2007; 196(Suppl 2):S205–S212. [PMID: 17940951]. [PubMed: 17940951]
9. Ksiazek TG, Rollin PE, Williams AJ, Bressler DS, Martin ML, Swane-poel R, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. *J Infect Dis*. 1999; 179(Suppl 1):S177–S187. [PMID: 9988182]. [PubMed: 9988182]
10. Trombley AR, Wachter L, Garrison J, Buckley-Beason VA, Jahrling J, Hensley LE, et al. Comprehensive panel of real-time Taq-Man polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. *Am J Trop Med Hyg*. 2010; 82:954–960. [PMID: 20439981]. [PubMed: 20439981]
11. Centers for Disease Control and Prevention. What U.S. Hospitals Need to Know to Prepare for Ebola Virus Disease. Atlanta, GA: Centers for Disease Control and Prevention; 2014. Accessed at <http://emergency.cdc.gov/coca/transcripts/2014/call-transcript-080514.asp> on 17 April 2015.
12. Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, McElroy AK, et al. Emory Serious Communicable Diseases Unit. Clinical care of two patients with Ebola virus disease in the United States. *N Engl J Med*. 2014; 371:2402–2409. [PMID: 25390460]. [PubMed: 25390460]
13. Kreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, de Heer G, Kluge S, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. *N Engl J Med*. 2014; 371:2394–2401. [PMID: 25337633]. [PubMed: 25337633]
14. Wolf T, Kann G, Becker S, Stephan C, Brodt HR, de Leuw P, et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. *Lancet*. 2014 [PMID: 25534190].
15. Parra JM, Salmerón OJ, Velasco M. The first case of Ebola virus disease acquired outside Africa [Letter]. *N Engl J Med*. 2014; 371:2439–2440. [PMID: 25409262]. [PubMed: 25409262]
16. Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A. Ebola virus disease in West Africa—clinical manifestations and management. *N Engl J Med*. 2014; 371:2054–2057. [PMID: 25372854]. [PubMed: 25372854]
17. Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, et al. CMX001-201 Clinical Study Group. CMX001 to prevent cytomegalovirus disease in

hematopoietic-cell transplantation. *N Engl J Med.* 2013; 369:1227–1236. [PMID: 24066743]. [PubMed: 24066743]

18. Fowler RA, Fletcher T, Fischer WA 2nd, Lamontagne F, Jacob S, Brett-Major D, et al. Caring for critically ill patients with Ebola virus disease Perspectives from West Africa. *Am J Respir Crit Care Med.* 2014; 190:733–737. [PMID: 25166884]. [PubMed: 25166884]
19. Ansumana R, Jacobsen KH, Sahr F, Idris M, Bangura H, Boie-Jalloh M, et al. Ebola in Freetown area, Sierra Leone—a case study of 581 patients [Letter]. *N Engl J Med.* 2015; 372:587–588. [PMID: 25539447]. [PubMed: 25539447]

## Appendix

Appendix Table 1

Laboratory Results for Patient 1, the First Imported Case of Ebola Virus Disease Diagnosed in the United States, September 2014\*

Variable	Illness Day (Date in 2014)														
	3 (26 September)	5 (28 September)	6 (29 September)	7 (30 September)	8 (1 October)	9 (2 October)	10 (3 October)	11 (4 October)	12 (5 October)	13 (6 October)	14 (7 October)	15 (8 October)			
Experimental therapy	-	-	-	-	-	-	-	-	-	-	-	-	BCV	BCV	-
Hematology															
Leukocyte count, $\times 10^9$ cells/L	3.08 (L)	3.13 (L)	7.01	9.68	-	16.26 (H)	16.63 (H)	17.30 (H)	22.99 (H) <sup>†</sup>	26.88 (H)	51.30 (H)	-	-	-	-
Neutrophil count, $\times 10^9$ cells/L	2.02	2.01	5.55	-	-	-	-	13.99 (H)	-	-	-	-	-	-	-
Lymphocyte count, $\times 10^9$ cells/L	0.77 (L)	1.06	1.30	2.23	-	-	-	1.82	-	-	-	-	-	-	-
Hemoglobin, g/dL	15.6	16.3	16.7	15.7	-	13.9	12.5	10.2	11.5	10.2	9.2	-	-	-	-
Platelet count, $\times 10^9$ cells/L	92 (L)	68 (L)	112 (L)	146	-	172	136	75 (L)	78 (L)	102 (L)	96 (L)	-	-	-	-
INR	-	1.2	-	1.3 (H)-1.7 (H)	1.7 (H)-1.9 (H)	2.0 (H) <sup>‡</sup>	1.8 (H)-2.1 (H) <sup>‡</sup>	1.6 (H)-2.0 (H)	1.3 (H)-1.4 (H)	1.3 (H)	1.2 (H)-1.3 (H)	1.5 (H)	-	-	-
PTT, s	-	48.7 (H)	-	52.8 (H)	-	-	-	-	-	-	-	-	-	-	-
Serum levels															
AST, U/L	94 (H)	518 (H)	1287 (H)	1308 (H)	-	1020 (H)	642 (H)	392 (H)	>3600 <sup>§</sup>	447 (H)	480 (H)	-	-	-	-
ALT, U/L	26	72 (H)	216 (H)	216 (H)	-	150 (H)	94 (H)	54 (H)	>3600 <sup>§</sup>	48 (H)	52 (H)	-	-	-	-
AP, U/L	56	141 (H)	254 (H)	430 (H)	-	591 (H)	339 (H)	190 (H)	308 (H)	328 (H)	276 (H)	-	-	-	-
Bilirubin, mg/dL	0.5	0.3	0.9	1.6 (H)	-	3.3 (H)	4.1 (H)	4.1 (H)	5.1 (H)	5.7 (H)	9.0 (H)	-	-	-	-
Albumin, g/dL	3.7	3.4	2.3 (L)	2.1 (L)		3.3	3.4	3.2 (L)	2.7 (L)	2.3 (L)	2.2 (L)	-	-	-	-
Creatinine, mg/dL	1.41 (H)	1.27 (H)	1.89 (H)	2.18 (H)	-	2.69 (H)	5.84 (H)	8.76 (H)	3.80 (H)	2.03 (H)	1.25 (H)	-	-	-	-
Lactate, mmol/L	-	-	-	2.27 (H)	-	3.00 (H)	2.80 (H)	2.57 (H)	6.57 (H)	6.57 (H)	4.62 (H)	19.07 (H)	-	-	-
Sodium, mmol/L	136	132 (L)	138	139	-	145	139	137	132 (L)	140	144	-	-	-	-
Potassium, mmol/L	3.7	3.5	3.5	3.1 (L)	-	3.4 (L)	3.8	4.1	4.8	3.4 (L)	4.0	-	-	-	-
Chloride, mmol/L	100	99	113 (H)	112 (H)	-	111 (H)	103	98	96 (L)	97 (L)	99	-	-	-	-
CO <sub>2</sub> content, mmol/L	27	20 (L)	15 (L)	16 (L)	-	18 (L)	17 (L)	18 (L)	18 (L)	23	28	-	-	-	-
Anion gap, mmol/L	9	13	10	11	-	16	19	19	18	20	17	-	-	-	-
LDH, U/L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	>4500
CK, U/L	-	-	-	-	-	-	-	-	1917	-	-	-	-	-	-
Maximum temperature, °C	39.4	39.6	39.4	39.3	40.1	40.1	39.6	38.2	37.4	AF	37.4	39.1	-	-	-
O <sub>2</sub> saturation, %	-	94-98	94-98	90-97	92-96	90-100	83-99	89-97	90-97	91-96	90-97	88	-	-	-
O <sub>2</sub> requirement	-	2 L/min (L)	2-3 L/min (L)	3-4 L/min (L)	2-4 L/min (L)	15 L/min (L)	15 L/min (L)	100%	80%-100%	90%	90%	90%	-	-	-
O <sub>2</sub> delivery method	-	NC	NC	NC	NC	NRB	NRB	ETT	ETT	ETT	ETT	ETT	-	-	-

Variable	Illness Day (Date in 2014)														
	3 (26 September)	5 (28 September)	6 (29 September)	7 (30 September)	8 (1 October)	9 (2 October)	10 (3 October)	11 (4 October)	12 (5 October)	13 (6 October)	14 (7 October)	15 (8 October)			
Blood EBOV qRT-PCR result	Positive	Positive	Positive	Positive	-	-	-	Positive	Positive	Positive	-	-			
Blood EBOV qRT-PCR Ct value	23 <sup>†</sup>	19	17	19	-	-	-	2.5	2.5	26	-	-			
EBOV IgM antibody titer	u/d	u/d	400	400	-	-	-	-	-	1600	-	-			
EBOV IgG antibody titer	u/d	u/d	u/d	u/d	-	-	-	-	-	u/d	-	-			

AF = afebrile; ALT = alanine aminotransferase; AP = alkaline phosphatase; AST = aspartate aminotransferase; BCV = brincidofovir; CK = creatine kinase; Ct = cycle threshold (lower values reflect higher viral loads); EBOV = Ebola virus; ETT = endotracheal tube; H = high (above reference range); INR = international normalized ratio; L = low (below reference range); LDH = lactate dehydrogenase; NC = nasal cannula; NRB = nonrebreather mask; PTT = partial thromboplastin time; qRT-PCR = quantitative reverse transcriptase polymerase chain reaction; u/d = undetectable level (negative result). Dashes indicate no results on these days.

\* qRT-PCR targeting the nucleoprotein gene was performed at the Centers for Disease Control and Prevention. Beginning 2 October, all laboratory results were from point-of-care testing (except lactate on 3 October).

<sup>†</sup>Treatment with corticosteroids was started.

<sup>‡</sup>Fresh frozen plasma infusions were initiated.

<sup>§</sup>Unreliable serum aminotransferase measurement due to presence of an interfering substance in the serum related to propofol. These values were therefore not shown in Figure 2.

<sup>||</sup>Albumin infusions were initiated.

<sup>¶</sup>Tested retrospectively from a residual blood specimen collected on 26 September.



Appendix Table 2

Laboratory Results for Patient 2, the First Domestically Acquired Ebola Virus Disease Case in the United States, October 2014

Variable	Illness Day (Date in 2014)														
	2 (11 October)	3 (12 October)	4 (13 October)	5 (14 October)	6 (15 October)	7 (16 October) (Transfer)	8 (17 October)	9 (18 October)	10 (19 October)	11 (20 October)	12 (21 October)	13 (22 October)	14 (23 October)	20 (29 October)	27 (5 November)
Experimental therapy	-	BCV, CVP	CVP, TKM-Ebola	ZMapp, TKM-Ebola	BCV, TKM-Ebola	-	-	-	-	-	-	-	-	-	-
Hematology															
Leukocyte count, $\times 10^9$ <i>cells/L</i>	4.10 (L)	2.03 (L)	-	3.52 (L)	4.03 (L)	3.39 (L)	4.63	5.64	6.52	7.01	7.25	5.73	5.62	7.51	5.45
Neutrophil count, $\times 10^9$ <i>cells/L</i>	3.01	1.64 (L)	-	2.97	3.04	1.76	1.61	2.01	2.52	3.34	3.39	2.75	2.70	4.91	2.93
Lymphocyte count, $\times 10^9$ <i>cells/L</i>	0.66 (L)	0.23 (L)	-	0.49 (L)	0.74 (L)	0.98	2.04	2.43	2.37	2.17	2.18	1.73	1.87	1.64	1.64
Hemoglobin, <i>g/dL</i>	13.9	12.6	-	10.5 (L)	10.4 (L)	11.8	12.0	10.9 (L)	12.2	13.1	13.3	13.1	12.4	11.8	11.5
Platelet count, $\times 10^9$ <i>cells/L</i>	343	193	-	67 (L)	94 (L)	108 (L)	122 (L)	166	214	290	340	375	417	601	457
Serum levels															
AST, <i>U/L</i>	27	29	63 (H)	140 (H)	223 (H)	224 (H)	286 (H)	337 (H)	216 (H)	152 (H)	104 (H)	83 (H)	65 (H)	26	27
ALT, <i>U/L</i>	26	28	53 (H)	74 (H)	191 (H)	245 (H)	311 (H)	398 (H)	376 (H)	348 (H)	300 (H)	236 (H)	188 (H)	65 (H)	38
AP, <i>U/L</i>	53	47	51	41 (L)	48	64	79	107	123	138	146	133	116	109 (H)	92
Bilirubin, <i>mg/dL</i>	0.1	0.1	0.2	0.2	0.3	0.4	0.8	0.8	0.9	0.9	0.9	0.8	0.8	0.5	0.3
Albumin, <i>g/dL</i>	3.8	3.4	3.4	3.9	3.8	4.1	4.3	4.1	4.3	4.2	4.5	4.4	4.4	4.1	3.5
Creatinine, <i>mg/dL</i>	0.76	0.62	0.65	0.59	0.59	0.62	0.3	0.5	0.4	0.6	0.5	0.6	0.5	0.6	0.6
Sodium, <i>mmol/L</i>	140	136	140	141	138	140	136	136	136	138	138	137	138	141	139
Potassium, <i>mmol/L</i>	3.7	3.5	3.9	3.9	3.7	6.4	3.7	3.7	3.9	4.3	4.0	4.2	3.9	3.8	3.7
Chloride, <i>mmol/L</i>	104	104	106	108	102	109	103	105	102	104	100	102	99	107	106
CO <sub>2</sub> content, <i>mmol/L</i>	23	23	25	25	26	23	30	29	29	28	29	31	29	22	24
Anion gap, <i>mmol/L</i>	10	5	9	8	10	8	6.7	5.7	8.9	10.3	13	8.2	13.9	12	9
LDH, <i>U/L</i>	-	-	-	608 (H)	318 (H)	-	-	-	-	-	-	-	-	-	-
CK, <i>U/L</i>	-	-	-	154	161	-	-	-	-	-	-	-	-	-	-
Maximum temperature, °C	38.2	39.7	40.0	38.6	38.3	AF	AF	AF	AF	AF	AF	AF	AF	AF	AF
Blood EBOV qRT-PCR result	Positive	Positive	Positive	u/d	Positive	u/d	u/d	u/d	u/d	u/d	u/d	u/d	u/d	u/d	u/d
Blood EBOV qRT-PCR Ct value	32	30	36	-	38	-	-	-	-	-	-	-	-	-	-
EBOV IgM antibody titer	u/d	u/d	u/d	400	400	1600	-	-	-	6400	-	-	-	-	-
EBOV IgG antibody titer	u/d	u/d	u/d	400	6400	1600	-	-	-	1600	-	-	-	-	-

AF = afébrile; ALT = alanine aminotransferase; AP = alkaline phosphatase; AST = aspartate aminotransferase; BCV = brincidofovir; CK = creatine kinase; Ct = cycle threshold (lower values reflect higher viral loads); CVP = convalescent plasma; EBOV = Ebola virus; H = high (above reference range); L = low (below reference range); LDH = lactate dehydrogenase; qRT-PCR = quantitative reverse transcriptase polymerase chain reaction; u/d = undetectable level (negative result). Dashes indicate no results on these days.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

RT-PCR performed at U.S. Army Medical Research Institute of Infectious Diseases, which measures nucleoprotein and glycoprotein. Initial qRT-PCR was performed at the Centers for Disease Control and Prevention, targeting the nucleoprotein gene.

<sup>†</sup>Result was also negative from urine and throat, rectal, and vaginal swabs.

<sup>‡</sup>Result was also negative from axillary skin sweat.

Appendix Table 3

Laboratory Results for Patient 3, the Second Domestically Acquired Ebola Virus Disease Case in the United States, October 2014

Variable	5 (14 October)	6 (15 October Transfer)	7 (16 October)	8 (17 October)	9 (18 October)	10 (19 October)	11 (20 October)	12 (21 October)	13 (22 October)	14 (23 October)	15 (24 October)	16 (25 October)	17 (26 October)	18 (27 October)	25 (3 November)	32 (10 November)	40 (18 November)
Experimental therapy	BCV	CVP	CVP	BCV	-	-	-	-	-	-	-	-	-	-	-	-	-
Hematology																	
Leukocyte count, $\times 10^9$ cells/L	2.67 (L)	3.55 (L)	6.2	4.8	6.3	6.3	5.6	6.6	6.0	6.1	5.4 (L)	5.2	5.8	6.2	5.8	4.8	6.1
Neutrophil count, $\times 10^9$ cells/L	1.95	2.22	-	-	-	-	-	-	-	-	-	-	-	-	2.3	2.5	3.8
Lymphocyte count, $\times 10^9$ cells/L	0.62 (L)	0.97	-	-	-	-	-	-	-	-	-	-	-	-	2.72	1.79	0.88
Hemoglobin, g/dL	15.8	14.5	12.2	12.2	12.2	12.2	13.5	13.9	12.2	12.6	11.2 (L)	10.9 (L)	11.1 (L)	12.1	12.7	13.5	14.4
Platelet count, $\times 10^9$ cells/L	120 (L)	114 (L)	197	116	140 (L)	195	236	309	305	346	341	320	311	336	248	206	170
Serum levels																	
AST, U/L	255 (H)	306 (H)	195 (H)	154 (H)	241 (H)	491 (H)	393 (H)	379 (H)	293 (H)	361 (H)	318 (H)	251 (H)	183 (H)	176 (H)	42	27	24
ALT, U/L	175 (H)	239 (H)	204 (H)	188 (H)	273 (H)	512 (H)	557 (H)	654 (H)	575 (H)	719 (H)	698 (H)	635 (H)	534 (H)	533 (H)	137	57	35
AP, U/L	70	58	53	62	60	71	80	80	69	82	64	58	58	62	76	72	65
Bilirubin, mg/dL	0.5	0.5	0.6	0.5	0.5	0.5	0.6	0.6	0.6	0.6	0.8	0.7	0.7	0.8	0.2	0.4	0.5
Albumin, g/dL	3.5	2.8 (L)	3.0 (L)	3.2 (L)	3.3 (L)	3.2 (L)	3.5	3.7	3.5	3.7	3.3 (L)	3.2 (L)	3.2 (L)	3.5	3.8	3.6	3.7
Creatinine, mg/dL	0.7	0.6	0.7	0.6	0.7	0.7	0.7	0.6	0.7	0.6	0.6	0.6	0.7	0.7	0.7	0.7	0.7
Sodium, mmol/L	136	136	136	141	149	143	141	142	138	140	139	138	137	138	137	139	137
Potassium, mmol/L	3.5	3.8	3.5	3.7	4.0	3.9	3.9	4.3	3.9	4.1	4.7	3.9	4.1	4.1	4.4	3.5	3.9
Chloride, mmol/L	102	108	106	109	111	107	107	105	105	107	107	108	108	107	105	109	108
CO <sub>2</sub> content, mmol/L	21	19	26	27	28	28	27	28	26	25	26	27	26	28	21	21	19
Anion gap, mmol/L	13	9	4	5	10	8	7	9	7	8	6	11	3	3	-	-	10
LDH, U/L	-	751	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
CK, U/L	-	238	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Maximum temperature, °C	38.9	38.9	AF	AF	AF	AF	AF	AF	AF	AF	AF	AF	AF	AF	AF	AF	AF
Blood EBOV qRT-PCR result	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive
Blood EBOV qFT-PCR Ct value	30	33	37	37	-	-	-	-	-	-	-	-	-	-	-	-	-
Urine EBOV qFT-PCR result	-	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive
Urine EBOV qFT-PCR Ct value	-	34	35	39	38	-	39.5	-	-	-	-	-	-	-	-	-	-
EBOV IgM antibody titer	u/d	u/d	400	1600	-	6400	6400	6400	6400	6400	>1600	-	-	-	-	-	-
EBOV IgG antibody titer	u/d	u/d	400	1600	-	1600	1600	6400	6400	6400	>1600	-	-	-	-	-	-

AF = afébrile; ALT = alanine aminotransferase; AP = alkaline phosphatase; AST = aspartate aminotransferase; BCV = brincidofovir; CK = creatine kinase; Ct = cycle threshold (lower values reflect higher viral loads); CVP = convalescent plasma; EBOV = Ebola virus; H = high (above reference range); L = low (below reference range); LDH = lactate dehydrogenase; qRT-PCR = quantitative reverse transcriptase polymerase chain reaction; u/d = undetectable level (negative result). Dashes indicate no results on these days.

\* Result was also negative from skin and vaginal fluid.

**EDITORS' NOTES****Context**

A cluster of Ebola virus disease (EVD) cases occurred in a hospital in Dallas, Texas.

**Contribution**


Detailed information is provided on the clinical course of the index case patient and 2 nurses who developed EVD after caring for him. The nurses were diagnosed early in the disease course. Management of all patients included close monitoring, full hemodynamic and other support, and use of experimental therapies. The index patient died, and the nurses survived.

**Caution**


The specific contribution of experimental therapies to survival could not be determined.

**Implication**

Survival from EVD may be improved with intensive care. Determination of additional benefits of specific therapies requires formal study.




**Figure 1. Clinical course of the index case and 2 secondary cases of Ebola virus disease**  
 Dates of symptom and fever onset, investigational therapeutics administered, and key events in the hospital course for the 3 patients are shown. BCV = brincidofovir; CVVHD = continuous venovenous hemodialysis; ED = emergency department; ICU = intensive care unit; RT-PCR = reverse transcriptase polymerase chain reaction.



**Figure 2. Timeline of laboratory results and treatments for patient 1**


Trends in serum aminotransferase levels, platelet count, and leukocyte count are shown in the top graph. Horizontal dotted bars denote the periods during which investigational therapeutics were administered, with individual doses indicated in solid color within those periods. Decrease in blood EBOV RNA levels (as reflected by increase in Ct values) and appearance of IgM antibodies to EBOV (indicated as reciprocal titers) are shown in the bottom graph. This patient did not develop detectable IgG antibodies to EBOV. ALT = alanine aminotransferase; AST = aspartate aminotransferase; Ct = cycle threshold; EBOV = Ebola virus.





**Figure 3. Timeline of laboratory results and treatments for patient 2**

Trends in serum aminotransferase levels, platelet count, and leukocyte count are shown in the top graph. Horizontal dotted bars denote the periods during which investigational therapeutics were administered, with individual doses indicated in solid color within those periods. Decrease in blood EBOV RNA levels (as reflected by increase in Ct values) and appearance of antibodies to EBOV (indicated as reciprocal titers) are shown in the bottom graph. ALT = alanine aminotransferase; AST = aspartate aminotransferase; Ct = cycle threshold; EBOV = Ebola virus.



**Figure 4. Timeline of laboratory results and treatments for patient 3**

Trends in serum aminotransferase levels, platelet count, and leukocyte count are shown in the top graph. Horizontal dotted bars denote the periods during which investigational therapeutics were administered, with individual doses indicated in solid color within those periods. Decrease in blood EBOV RNA levels (as reflected by increase in Ct values) and appearance of antibodies to EBOV (indicated as reciprocal titers) are shown in the bottom graph. Suspected illness onset date was 10 October 2014; fever onset date was 14 October

2014. ALT = alanine aminotransferase; AST = aspartate aminotransferase; Ct = cycle threshold; EBOV = Ebola virus.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1

Investigational Therapeutics Administered to the First 3 Patients Diagnosed With Ebola Virus Disease in the United States

Investigational Treatment	Sponsor	Mechanism	Illness Day of Administration	Dose Administered	Possible Adverse Effects
<b>Patient 1</b> Brincidofovir	Chimerix	eIND application	11, 14	200-mg loading dose (day 11), then 100 mg given by orogastric tube (day 14)	Unknown
<b>Patient 2</b> Brincidofovir	Chimerix	eIND application	3, 6	200-mg oral loading dose (day 3), then 100 mg (day 6)	Elevations in serum ALT/AST levels
Convalescent plasma	–	eIND application for donated plasma	3, 4	500-mL IV infusions	None
TKM-Ebola*	Tekmira Pharmaceuticals	eIND application	4, 5, 6	Initial IV dose of 0.3 mg/kg of body weight, then 0.24 mg/kg on subsequent days	Hypotension, fever, and chills after first infusion
ZMapp triple monoclonal antibodies	Mapp Biopharmaceutical	eIND application	5	Single IV dose of 44.8 mg/kg (2724 mg)	None
<b>Patient 3</b> Brincidofovir	Chimerix	eIND application	5, 8 <sup>†</sup>	200-mg oral loading dose (day 5), then 100 mg (day 8)	Elevations in serum ALT/AST levels
Convalescent plasma	–	eIND application for donated plasma	6, 7 <sup>†</sup>	600-mL IV infusion (day 6), then 500 mL (day 7)	None

ALT = alanine aminotransferase; AST = aspartate aminotransferase; eIND = emergency Investigational New Drug; IV = intravenous.

\* Small interfering RNA molecule.

<sup>†</sup> Day 1 was the day of earliest suspected illness onset (10 October 2014); fever onset was 14 October 2014.